Methyl-CpG binding protein 2 (MeCP2) (MeCP2)

Methyl-CpG binding protein 2 (MeCP2) is a nuclear protein that binds methylated DNA, particularly at CpG sites, and plays a critical role in regulating gene expression and chromatin structure[1]. MeCP2 was originally characterized as a gene silencer that recruits histone deacetylases and corepressors to methylated DNA, but more recently it has been recognized as a multifunctional regulator of transcription, chromatin architecture, and RNA splicing[1]. MeCP2 is composed of several domains, including a methyl-CpG-binding domain (MBD), a transcriptional repression domain (TRD), an N-terminal domain, and two C-terminal domains (CTD-α and CTD-β); it also contains AT-hook motifs that contribute to DNA binding[1][4]. The MBD is necessary and sufficient for binding methylated DNA, while the TRD mediates interactions with transcriptional corepressors and other regulatory complexes[1][4]. Functional analysis indicates that full-length MeCP2 is largely intrinsically disordered, with regions of order corresponding to its functional domains[1]. MeCP2 is a central player in the pathogenesis of Rett syndrome, a severe neurodevelopmental disorder, and mutations or disruptions in MeCP2 are also associated with other forms of intellectual disability and autism spectrum disorders[1]. The protein’s role in disease is dose-sensitive: both loss-of-function and gain-of-function mutations can cause neurological dysfunction[1]. Despite its central role in disease, MeCP2 is not yet a direct therapeutic target for approved drugs. However, understanding its mechanisms and the effects of its mutations continues to inform genetic therapies and research into epigenetic modulators for neurodevelopmental disorders[1].

Other names

MeCp-2 proteinMeCp2AUTSX3MRX16MRX79MRXS13MRXSLPPMXRSRTSRTT

Transcriptional repression via recruitment of histone deacetylases and corepressors, Chromatin compaction independent of DNA methylation, Transcriptional activation in some contexts